Endocrine, Metabolic and Immune Disorders - Drug Targets- Impact Score, Ranking, SJR, h-index, Citescore, Rating, Publisher, ISSN, and Other Important Details

About Endocrine, Metabolic and Immune Disorders - Drug Targets

Endocrine, Metabolic and Immune Disorders - Drug Targets is a journal published by Bentham Science Publishers B.V.. This journal covers the area[s] related to Endocrinology, Diabetes and Metabolism, Immunology and Allergy, etc. The coverage history of this journal is as follows: 2006-2022. The rank of this journal is 11874. This journal's impact score, h-index, and SJR are 1.97, 60, and 0.427, respectively. The ISSN of this journal is/are as follows: 18715303.

The best quartile of Endocrine, Metabolic and Immune Disorders - Drug Targets is Q3. This journal has received a total of 1139 citations during the last three years (Preceding 2022).

Endocrine, Metabolic and Immune Disorders - Drug Targets Impact Score 2022-2023

The latest impact score (IS) of the Endocrine, Metabolic and Immune Disorders - Drug Targets is 1.97. It is computed in the year 2023 as per its definition and based on Scopus data. 1.97

It is decreased by a factor of around 0.34, and the percentage change is -14.72% compared to the preceding year 2021, indicating a falling trend.

The impact score (IS), also denoted as the Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.

Prediction of Endocrine, Metabolic and Immune Disorders - Drug Targets Impact Score 2023

Impact Score 2022 of Endocrine, Metabolic and Immune Disorders - Drug Targets is 1.97. If a similar downward trend continues, IS may decrease in 2023 as well.

Endocrine, Metabolic and Immune Disorders - Drug Targets h-index

 

The h-index of Endocrine, Metabolic and Immune Disorders - Drug Targets is 60. By definition of the h-index, this journal has at least 60 published articles with more than 60 citations.

What is h-index?

The h-index (also known as the Hirsch index or Hirsh index) is a scientometric parameter used to evaluate the scientific impact of the publications and journals. It is defined as the maximum value of h such that the given Journal has published at least h papers and each has at least h citations.

Endocrine, Metabolic and Immune Disorders - Drug Targets ISSN

The International Standard Serial Number (ISSN) of Endocrine, Metabolic and Immune Disorders - Drug Targets is/are as follows: 18715303.

The ISSN is a unique 8-digit identifier for a specific publication like Magazine or Journal. The ISSN is used in the postal system and in the publishing world to identify the articles that are published in journals, magazines, newsletters, etc. This is the number assigned to your article by the publisher, and it is the one you will use to reference your article within the library catalogues.

ISSN code (also called as "ISSN structure" or "ISSN syntax") can be expressed as follows: NNNN-NNNC
Here, N is in the set {0,1,2,3...,9}, a digit character, and C is in {0,1,2,3,...,9,X}

Endocrine, Metabolic and Immune Disorders - Drug Targets Ranking and SCImago Journal Rank (SJR)

The Endocrine, Metabolic and Immune Disorders - Drug Targets is ranked 11874 among 27955 Journals, Conferences, and Book Series. As per SJR, this journal is ranked 0.427.

SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.

Endocrine, Metabolic and Immune Disorders - Drug Targets Publisher

The publisher of Endocrine, Metabolic and Immune Disorders - Drug Targets is Bentham Science Publishers B.V.. The publishing house of this journal is located in the United Arab Emirates. Its coverage history is as follows: 2006-2022.

Call For Papers (CFPs)

Please check the official website of this journal to find out the complete details and Call For Papers (CFPs).

Abbreviation

The International Organization for Standardization 4 (ISO 4) abbreviation of Endocrine, Metabolic and Immune Disorders - Drug Targets is Endocr. Metab. Immune Disord. - Drug Targets. ISO 4 is an international standard which defines a uniform and consistent system for the abbreviation of serial publication titles, which are published regularly. The primary use of ISO 4 is to abbreviate or shorten the names of scientific journals using the technique of List of Title Word Abbreviations (LTWA).

As ISO 4 is an international standard, the abbreviation ('Endocr. Metab. Immune Disord. - Drug Targets') can be used for citing, indexing, abstraction, and referencing purposes.

How to publish in Endocrine, Metabolic and Immune Disorders - Drug Targets

If your area of research or discipline is related to Endocrinology, Diabetes and Metabolism, Immunology and Allergy, etc., please check the journal's official website to understand the complete publication process.

Acceptance Rate

There are several factors that influence the acceptance rate of any academic journal. Here are some critical parameters that are considered while calculating the acceptance rate:

• Interest/demand of researchers/scientists for publishing in a specific journal/conference.
• The complexity of the peer review process and timeline.
• Time taken from draft submission to final publication.
• Number of submissions received and acceptance slots
• And Many More.

The simplest way to find out the acceptance rate or rejection rate of a Journal/Conference is to check with the journal's/conference's editorial team through emails or through the official website.

Credits and Sources

• Scimago Journal & Country Rank (SJR), https://www.scimagojr.com/
• Journal Impact Factor, https://clarivate.com/
• Issn.org, https://www.issn.org/
• Scopus, https://www.scopus.com/